Global Tumour Neoantigens Production, Demand and Key Producers, 2022-2028
Tumor neoantigens, as their name implies, are antigens that are not expressed in normal tissues but are expressed only in tumor tissues, including those produced by the integration of oncogenic viruses into the genome and mutant proteins, and neoantigens are not only highly specific but also strongly immunogenic because of their unselected thymus negative screening.
This report studies the global Tumour Neoantigens production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Tumour Neoantigens, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Tumour Neoantigens that contribute to its increasing demand across many markets.
The global Tumour Neoantigens market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global Tumour Neoantigens total production and demand, 2017-2028, (K Units)
Global Tumour Neoantigens total production value, 2017-2028, (USD Million)
Global Tumour Neoantigens production by region & country, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global Tumour Neoantigens consumption by region & country, CAGR, 2017-2028 & (K Units)
U.S. VS China: Tumour Neoantigens domestic production, consumption, key domestic manufacturers and share
Global Tumour Neoantigens production by manufacturer, production, price, value and market share 2017-2022, (USD Million) & (K Units)
Global Tumour Neoantigens production by Type, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global Tumour Neoantigens production by Application production, value, CAGR, 2017-2028, (USD Million) & (K Units)
This reports profiles key players in the global Tumour Neoantigens market based on the following parameters – headquarters, production locations, products portfolio, Tumour Neoantigens revenue, sales, average price and gross margin, recent developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Tumour Neoantigens market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global Tumour Neoantigens Market, By Region:
1. How big is the global Tumour Neoantigens market?
2. What is the demand of the global Tumour Neoantigens market?
3. What is the year over year growth of the global Tumour Neoantigens market?
4. What is the production and production value of the global Tumour Neoantigens market?
5. Who are the key producers in the global Tumour Neoantigens market?
6. What are the growth factors driving the market demand?
This report studies the global Tumour Neoantigens production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Tumour Neoantigens, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Tumour Neoantigens that contribute to its increasing demand across many markets.
The global Tumour Neoantigens market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global Tumour Neoantigens total production and demand, 2017-2028, (K Units)
Global Tumour Neoantigens total production value, 2017-2028, (USD Million)
Global Tumour Neoantigens production by region & country, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global Tumour Neoantigens consumption by region & country, CAGR, 2017-2028 & (K Units)
U.S. VS China: Tumour Neoantigens domestic production, consumption, key domestic manufacturers and share
Global Tumour Neoantigens production by manufacturer, production, price, value and market share 2017-2022, (USD Million) & (K Units)
Global Tumour Neoantigens production by Type, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global Tumour Neoantigens production by Application production, value, CAGR, 2017-2028, (USD Million) & (K Units)
This reports profiles key players in the global Tumour Neoantigens market based on the following parameters – headquarters, production locations, products portfolio, Tumour Neoantigens revenue, sales, average price and gross margin, recent developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Tumour Neoantigens market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global Tumour Neoantigens Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Common Neoantigens
- Individualized Neoantigens
- T Cell Adoptive Therapy
- DC Therapy
- Therapeutic Vaccines
- Other
- Achilles Therapeutics plc
- Advaxis Immunotherapies
- Genocea
- Gradalis, Inc
- Gritstone bio
- Iovance Biotherapetics Inc
- Medigene AG
- BioNTech SE
- Lilly
- Scicomvisuals
- Moderna, Inc
- F. Hoffmann-La Roche Ltd
- Merck KGaA
- Sun Pharmaceutical Industries Ltd
1. How big is the global Tumour Neoantigens market?
2. What is the demand of the global Tumour Neoantigens market?
3. What is the year over year growth of the global Tumour Neoantigens market?
4. What is the production and production value of the global Tumour Neoantigens market?
5. Who are the key producers in the global Tumour Neoantigens market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Tumour Neoantigens Introduction
1.2 World Tumour Neoantigens Supply & Forecast
1.2.1 World Tumour Neoantigens Production Value (2017 & 2021 & 2028)
1.2.2 World Tumour Neoantigens Production (2017-2028)
1.2.3 World Tumour Neoantigens Pricing Trends (2017-2028)
1.3 World Tumour Neoantigens Production by Region
1.3.1 World Tumour Neoantigens Production Value by Region (2017-2028)
1.3.2 World Tumour Neoantigens Production by Region (2017-2028)
1.3.3 World Tumour Neoantigens Average Price by Region (2017-2028)
1.3.4 North America Tumour Neoantigens Production (2017-2028)
1.3.5 Europe Tumour Neoantigens Production (2017-2028)
1.3.6 China Tumour Neoantigens Production (2017-2028)
1.3.7 Japan Tumour Neoantigens Production (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 Tumour Neoantigens Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Tumour Neoantigens Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Tumour Neoantigens Demand (2017-2028)
2.2 World Tumour Neoantigens Consumption by Region
2.2.1 World Tumour Neoantigens Consumption by Region (2017-2022)
2.2.2 World Tumour Neoantigens Consumption Forecast by Region (2023-2028)
2.3 United States Tumour Neoantigens Consumption (2017-2028)
2.4 China Tumour Neoantigens Consumption (2017-2028)
2.5 Europe Tumour Neoantigens Consumption (2017-2028)
2.6 Japan Tumour Neoantigens Consumption (2017-2028)
2.7 South Korea Tumour Neoantigens Consumption (2017-2028)
2.8 ASEAN Tumour Neoantigens Consumption (2017-2028)
2.9 India Tumour Neoantigens Consumption (2017-2028)
3 WORLD TUMOUR NEOANTIGENS MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Tumour Neoantigens Production Value by Manufacturer (2017-2022)
3.2 World Tumour Neoantigens Production by Manufacturer (2017-2022)
3.3 World Tumour Neoantigens Average Price by Manufacturer (2017-2022)
3.4 Tumour Neoantigens Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Tumour Neoantigens Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Tumour Neoantigens in 2021
3.5.3 Global Concentration Ratios (CR8) for Tumour Neoantigens in 2021
3.6 Tumour Neoantigens Market: Overall Company Footprint Analysis
3.6.1 Tumour Neoantigens Market: Region Footprint
3.6.2 Tumour Neoantigens Market: Company Product Type Footprint
3.6.3 Tumour Neoantigens Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Tumour Neoantigens Production Value Comparison
4.1.1 United States VS China: Tumour Neoantigens Production Value Comparison (2017 & 2021 & 2028)
4.1.2 United States VS China: Tumour Neoantigens Production Value Market Share Comparison (2017 & 2021 & 2028)
4.2 United States VS China: Tumour Neoantigens Production Comparison
4.2.1 United States VS China: Tumour Neoantigens Production Comparison (2017 & 2021 & 2028)
4.2.2 United States VS China: Tumour Neoantigens Production Market Share Comparison (2017 & 2021 & 2028)
4.3 United States VS China: Tumour Neoantigens Consumption Comparison
4.3.1 United States VS China: Tumour Neoantigens Consumption Comparison (2017 & 2021 & 2028)
4.3.2 United States VS China: Tumour Neoantigens Consumption Market Share Comparison (2017 & 2021 & 2028)
4.4 United States Tumour Neoantigens Key Producers and Market Share, 2017-2022
4.4.1 Major Manufacturer of Tumour Neoantigens in United States, Company Headquarters and Production Place (States, Country)
4.4.2 United States Tumour Neoantigens Production Value by Domestic Manufacturer, (2017-2022)
4.4.3 United States Tumour Neoantigens Production by Domestic Manufacturer, (2017-2022)
4.5 China Tumour Neoantigens Key Producers and Market Share, 2017-2022
4.5.1 Major Manufacturer of Tumour Neoantigens in China, Company Headquarters and Production Place (Province, Country)
4.5.2 China Tumour Neoantigens Production Value by Domestic Manufacturer, (2017-2022)
4.5.3 China Tumour Neoantigens Production by Domestic Manufacturer, (2017-2022)
4.6 Rest of World Tumour Neoantigens Key Producers and Market Share, 2017-2022
4.6.1 Major Manufacturer of Tumour Neoantigens in Rest of World, Company Headquarters and Production Place (State, Country)
4.6.2 Rest of World Tumour Neoantigens Production Value by Domestic Manufacturer, (2017-2022)
4.6.3 Rest of World Tumour Neoantigens Production by Domestic Manufacturer, (2017-2022)
5 MARKET ANALYSIS BY TYPE
5.1 World Tumour Neoantigens Market Size Overview by Type: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Type
5.2.1 Common Neoantigens
5.2.2 Individualized Neoantigens
5.3 Market Segment by Type
5.3.1 World Tumour Neoantigens Production by Type (2017-2028)
5.3.2 World Tumour Neoantigens Production Value by Type (2017-2028)
5.3.3 World Tumour Neoantigens Average Price by Type (2017-2028)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Tumour Neoantigens Market Size Overview by Application: 2017 VS 2021 VS 2028
6.2 Segment Introduction by Application
6.2.1 T Cell Adoptive Therapy
6.2.2 DC Therapy
6.2.3 Therapeutic Vaccines
6.2.4 Other
6.3 Market Segment by Application
6.3.1 World Tumour Neoantigens Production by Application (2017-2028)
6.3.2 World Tumour Neoantigens Production Value by Application (2017-2028)
6.3.3 World Tumour Neoantigens Average Price by Application (2017-2028)
7 COMPANY PROFILES
7.1 Achilles Therapeutics plc
7.1.1 Achilles Therapeutics plc Details
7.1.2 Achilles Therapeutics plc Major Business
7.1.3 Achilles Therapeutics plc Tumour Neoantigens Product and Services
7.1.4 Achilles Therapeutics plc Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.1.5 Achilles Therapeutics plc Recent Developments/Updates
7.1.6 Achilles Therapeutics plc Competitive Strengths & Weaknesses
7.2 Advaxis Immunotherapies
7.2.1 Advaxis Immunotherapies Details
7.2.2 Advaxis Immunotherapies Major Business
7.2.3 Advaxis Immunotherapies Tumour Neoantigens Product and Services
7.2.4 Advaxis Immunotherapies Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.2.5 Advaxis Immunotherapies Recent Developments/Updates
7.2.6 Advaxis Immunotherapies Competitive Strengths & Weaknesses
7.3 Genocea
7.3.1 Genocea Details
7.3.2 Genocea Major Business
7.3.3 Genocea Tumour Neoantigens Product and Services
7.3.4 Genocea Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.3.5 Genocea Recent Developments/Updates
7.3.6 Genocea Competitive Strengths & Weaknesses
7.4 Gradalis, Inc
7.4.1 Gradalis, Inc Details
7.4.2 Gradalis, Inc Major Business
7.4.3 Gradalis, Inc Tumour Neoantigens Product and Services
7.4.4 Gradalis, Inc Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.4.5 Gradalis, Inc Recent Developments/Updates
7.4.6 Gradalis, Inc Competitive Strengths & Weaknesses
7.5 Gritstone bio
7.5.1 Gritstone bio Details
7.5.2 Gritstone bio Major Business
7.5.3 Gritstone bio Tumour Neoantigens Product and Services
7.5.4 Gritstone bio Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.5.5 Gritstone bio Recent Developments/Updates
7.5.6 Gritstone bio Competitive Strengths & Weaknesses
7.6 Iovance Biotherapetics Inc
7.6.1 Iovance Biotherapetics Inc Details
7.6.2 Iovance Biotherapetics Inc Major Business
7.6.3 Iovance Biotherapetics Inc Tumour Neoantigens Product and Services
7.6.4 Iovance Biotherapetics Inc Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.6.5 Iovance Biotherapetics Inc Recent Developments/Updates
7.6.6 Iovance Biotherapetics Inc Competitive Strengths & Weaknesses
7.7 Medigene AG
7.7.1 Medigene AG Details
7.7.2 Medigene AG Major Business
7.7.3 Medigene AG Tumour Neoantigens Product and Services
7.7.4 Medigene AG Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.7.5 Medigene AG Recent Developments/Updates
7.7.6 Medigene AG Competitive Strengths & Weaknesses
7.8 BioNTech SE
7.8.1 BioNTech SE Details
7.8.2 BioNTech SE Major Business
7.8.3 BioNTech SE Tumour Neoantigens Product and Services
7.8.4 BioNTech SE Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.8.5 BioNTech SE Recent Developments/Updates
7.8.6 BioNTech SE Competitive Strengths & Weaknesses
7.9 Lilly
7.9.1 Lilly Details
7.9.2 Lilly Major Business
7.9.3 Lilly Tumour Neoantigens Product and Services
7.9.4 Lilly Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.9.5 Lilly Recent Developments/Updates
7.9.6 Lilly Competitive Strengths & Weaknesses
7.10 Scicomvisuals
7.10.1 Scicomvisuals Details
7.10.2 Scicomvisuals Major Business
7.10.3 Scicomvisuals Tumour Neoantigens Product and Services
7.10.4 Scicomvisuals Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.10.5 Scicomvisuals Recent Developments/Updates
7.10.6 Scicomvisuals Competitive Strengths & Weaknesses
7.11 Moderna, Inc
7.11.1 Moderna, Inc Details
7.11.2 Moderna, Inc Major Business
7.11.3 Moderna, Inc Tumour Neoantigens Product and Services
7.11.4 Moderna, Inc Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.11.5 Moderna, Inc Recent Developments/Updates
7.11.6 Moderna, Inc Competitive Strengths & Weaknesses
7.12 F. Hoffmann-La Roche Ltd
7.12.1 F. Hoffmann-La Roche Ltd Details
7.12.2 F. Hoffmann-La Roche Ltd Major Business
7.12.3 F. Hoffmann-La Roche Ltd Tumour Neoantigens Product and Services
7.12.4 F. Hoffmann-La Roche Ltd Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.12.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
7.12.6 F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses
7.13 Merck KGaA
7.13.1 Merck KGaA Details
7.13.2 Merck KGaA Major Business
7.13.3 Merck KGaA Tumour Neoantigens Product and Services
7.13.4 Merck KGaA Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.13.5 Merck KGaA Recent Developments/Updates
7.13.6 Merck KGaA Competitive Strengths & Weaknesses
7.14 Sun Pharmaceutical Industries Ltd
7.14.1 Sun Pharmaceutical Industries Ltd Details
7.14.2 Sun Pharmaceutical Industries Ltd Major Business
7.14.3 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product and Services
7.14.4 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.14.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
7.14.6 Sun Pharmaceutical Industries Ltd Competitive Strengths & Weaknesses
8 RAW MATERIAL AND INDUSTRY CHAIN
8.1 Raw Material of Tumour Neoantigens and Key Manufacturers
8.2 Tumour Neoantigens Manufacturing Costs
8.3 Tumour Neoantigens Production Process
8.4 Tumour Neoantigens Industrial Chain
9 DISTRIBUTION CHANNEL ANALYSIS
9.1 Distribution Channel Breakdown for Tumour Neoantigens Shipments (%): 2017-2028
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 Tumour Neoantigens Typical Distributors
9.3 Tumour Neoantigens Typical Customers
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
1.1 Tumour Neoantigens Introduction
1.2 World Tumour Neoantigens Supply & Forecast
1.2.1 World Tumour Neoantigens Production Value (2017 & 2021 & 2028)
1.2.2 World Tumour Neoantigens Production (2017-2028)
1.2.3 World Tumour Neoantigens Pricing Trends (2017-2028)
1.3 World Tumour Neoantigens Production by Region
1.3.1 World Tumour Neoantigens Production Value by Region (2017-2028)
1.3.2 World Tumour Neoantigens Production by Region (2017-2028)
1.3.3 World Tumour Neoantigens Average Price by Region (2017-2028)
1.3.4 North America Tumour Neoantigens Production (2017-2028)
1.3.5 Europe Tumour Neoantigens Production (2017-2028)
1.3.6 China Tumour Neoantigens Production (2017-2028)
1.3.7 Japan Tumour Neoantigens Production (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 Tumour Neoantigens Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Tumour Neoantigens Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Tumour Neoantigens Demand (2017-2028)
2.2 World Tumour Neoantigens Consumption by Region
2.2.1 World Tumour Neoantigens Consumption by Region (2017-2022)
2.2.2 World Tumour Neoantigens Consumption Forecast by Region (2023-2028)
2.3 United States Tumour Neoantigens Consumption (2017-2028)
2.4 China Tumour Neoantigens Consumption (2017-2028)
2.5 Europe Tumour Neoantigens Consumption (2017-2028)
2.6 Japan Tumour Neoantigens Consumption (2017-2028)
2.7 South Korea Tumour Neoantigens Consumption (2017-2028)
2.8 ASEAN Tumour Neoantigens Consumption (2017-2028)
2.9 India Tumour Neoantigens Consumption (2017-2028)
3 WORLD TUMOUR NEOANTIGENS MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Tumour Neoantigens Production Value by Manufacturer (2017-2022)
3.2 World Tumour Neoantigens Production by Manufacturer (2017-2022)
3.3 World Tumour Neoantigens Average Price by Manufacturer (2017-2022)
3.4 Tumour Neoantigens Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Tumour Neoantigens Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Tumour Neoantigens in 2021
3.5.3 Global Concentration Ratios (CR8) for Tumour Neoantigens in 2021
3.6 Tumour Neoantigens Market: Overall Company Footprint Analysis
3.6.1 Tumour Neoantigens Market: Region Footprint
3.6.2 Tumour Neoantigens Market: Company Product Type Footprint
3.6.3 Tumour Neoantigens Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Tumour Neoantigens Production Value Comparison
4.1.1 United States VS China: Tumour Neoantigens Production Value Comparison (2017 & 2021 & 2028)
4.1.2 United States VS China: Tumour Neoantigens Production Value Market Share Comparison (2017 & 2021 & 2028)
4.2 United States VS China: Tumour Neoantigens Production Comparison
4.2.1 United States VS China: Tumour Neoantigens Production Comparison (2017 & 2021 & 2028)
4.2.2 United States VS China: Tumour Neoantigens Production Market Share Comparison (2017 & 2021 & 2028)
4.3 United States VS China: Tumour Neoantigens Consumption Comparison
4.3.1 United States VS China: Tumour Neoantigens Consumption Comparison (2017 & 2021 & 2028)
4.3.2 United States VS China: Tumour Neoantigens Consumption Market Share Comparison (2017 & 2021 & 2028)
4.4 United States Tumour Neoantigens Key Producers and Market Share, 2017-2022
4.4.1 Major Manufacturer of Tumour Neoantigens in United States, Company Headquarters and Production Place (States, Country)
4.4.2 United States Tumour Neoantigens Production Value by Domestic Manufacturer, (2017-2022)
4.4.3 United States Tumour Neoantigens Production by Domestic Manufacturer, (2017-2022)
4.5 China Tumour Neoantigens Key Producers and Market Share, 2017-2022
4.5.1 Major Manufacturer of Tumour Neoantigens in China, Company Headquarters and Production Place (Province, Country)
4.5.2 China Tumour Neoantigens Production Value by Domestic Manufacturer, (2017-2022)
4.5.3 China Tumour Neoantigens Production by Domestic Manufacturer, (2017-2022)
4.6 Rest of World Tumour Neoantigens Key Producers and Market Share, 2017-2022
4.6.1 Major Manufacturer of Tumour Neoantigens in Rest of World, Company Headquarters and Production Place (State, Country)
4.6.2 Rest of World Tumour Neoantigens Production Value by Domestic Manufacturer, (2017-2022)
4.6.3 Rest of World Tumour Neoantigens Production by Domestic Manufacturer, (2017-2022)
5 MARKET ANALYSIS BY TYPE
5.1 World Tumour Neoantigens Market Size Overview by Type: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Type
5.2.1 Common Neoantigens
5.2.2 Individualized Neoantigens
5.3 Market Segment by Type
5.3.1 World Tumour Neoantigens Production by Type (2017-2028)
5.3.2 World Tumour Neoantigens Production Value by Type (2017-2028)
5.3.3 World Tumour Neoantigens Average Price by Type (2017-2028)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Tumour Neoantigens Market Size Overview by Application: 2017 VS 2021 VS 2028
6.2 Segment Introduction by Application
6.2.1 T Cell Adoptive Therapy
6.2.2 DC Therapy
6.2.3 Therapeutic Vaccines
6.2.4 Other
6.3 Market Segment by Application
6.3.1 World Tumour Neoantigens Production by Application (2017-2028)
6.3.2 World Tumour Neoantigens Production Value by Application (2017-2028)
6.3.3 World Tumour Neoantigens Average Price by Application (2017-2028)
7 COMPANY PROFILES
7.1 Achilles Therapeutics plc
7.1.1 Achilles Therapeutics plc Details
7.1.2 Achilles Therapeutics plc Major Business
7.1.3 Achilles Therapeutics plc Tumour Neoantigens Product and Services
7.1.4 Achilles Therapeutics plc Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.1.5 Achilles Therapeutics plc Recent Developments/Updates
7.1.6 Achilles Therapeutics plc Competitive Strengths & Weaknesses
7.2 Advaxis Immunotherapies
7.2.1 Advaxis Immunotherapies Details
7.2.2 Advaxis Immunotherapies Major Business
7.2.3 Advaxis Immunotherapies Tumour Neoantigens Product and Services
7.2.4 Advaxis Immunotherapies Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.2.5 Advaxis Immunotherapies Recent Developments/Updates
7.2.6 Advaxis Immunotherapies Competitive Strengths & Weaknesses
7.3 Genocea
7.3.1 Genocea Details
7.3.2 Genocea Major Business
7.3.3 Genocea Tumour Neoantigens Product and Services
7.3.4 Genocea Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.3.5 Genocea Recent Developments/Updates
7.3.6 Genocea Competitive Strengths & Weaknesses
7.4 Gradalis, Inc
7.4.1 Gradalis, Inc Details
7.4.2 Gradalis, Inc Major Business
7.4.3 Gradalis, Inc Tumour Neoantigens Product and Services
7.4.4 Gradalis, Inc Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.4.5 Gradalis, Inc Recent Developments/Updates
7.4.6 Gradalis, Inc Competitive Strengths & Weaknesses
7.5 Gritstone bio
7.5.1 Gritstone bio Details
7.5.2 Gritstone bio Major Business
7.5.3 Gritstone bio Tumour Neoantigens Product and Services
7.5.4 Gritstone bio Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.5.5 Gritstone bio Recent Developments/Updates
7.5.6 Gritstone bio Competitive Strengths & Weaknesses
7.6 Iovance Biotherapetics Inc
7.6.1 Iovance Biotherapetics Inc Details
7.6.2 Iovance Biotherapetics Inc Major Business
7.6.3 Iovance Biotherapetics Inc Tumour Neoantigens Product and Services
7.6.4 Iovance Biotherapetics Inc Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.6.5 Iovance Biotherapetics Inc Recent Developments/Updates
7.6.6 Iovance Biotherapetics Inc Competitive Strengths & Weaknesses
7.7 Medigene AG
7.7.1 Medigene AG Details
7.7.2 Medigene AG Major Business
7.7.3 Medigene AG Tumour Neoantigens Product and Services
7.7.4 Medigene AG Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.7.5 Medigene AG Recent Developments/Updates
7.7.6 Medigene AG Competitive Strengths & Weaknesses
7.8 BioNTech SE
7.8.1 BioNTech SE Details
7.8.2 BioNTech SE Major Business
7.8.3 BioNTech SE Tumour Neoantigens Product and Services
7.8.4 BioNTech SE Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.8.5 BioNTech SE Recent Developments/Updates
7.8.6 BioNTech SE Competitive Strengths & Weaknesses
7.9 Lilly
7.9.1 Lilly Details
7.9.2 Lilly Major Business
7.9.3 Lilly Tumour Neoantigens Product and Services
7.9.4 Lilly Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.9.5 Lilly Recent Developments/Updates
7.9.6 Lilly Competitive Strengths & Weaknesses
7.10 Scicomvisuals
7.10.1 Scicomvisuals Details
7.10.2 Scicomvisuals Major Business
7.10.3 Scicomvisuals Tumour Neoantigens Product and Services
7.10.4 Scicomvisuals Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.10.5 Scicomvisuals Recent Developments/Updates
7.10.6 Scicomvisuals Competitive Strengths & Weaknesses
7.11 Moderna, Inc
7.11.1 Moderna, Inc Details
7.11.2 Moderna, Inc Major Business
7.11.3 Moderna, Inc Tumour Neoantigens Product and Services
7.11.4 Moderna, Inc Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.11.5 Moderna, Inc Recent Developments/Updates
7.11.6 Moderna, Inc Competitive Strengths & Weaknesses
7.12 F. Hoffmann-La Roche Ltd
7.12.1 F. Hoffmann-La Roche Ltd Details
7.12.2 F. Hoffmann-La Roche Ltd Major Business
7.12.3 F. Hoffmann-La Roche Ltd Tumour Neoantigens Product and Services
7.12.4 F. Hoffmann-La Roche Ltd Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.12.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
7.12.6 F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses
7.13 Merck KGaA
7.13.1 Merck KGaA Details
7.13.2 Merck KGaA Major Business
7.13.3 Merck KGaA Tumour Neoantigens Product and Services
7.13.4 Merck KGaA Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.13.5 Merck KGaA Recent Developments/Updates
7.13.6 Merck KGaA Competitive Strengths & Weaknesses
7.14 Sun Pharmaceutical Industries Ltd
7.14.1 Sun Pharmaceutical Industries Ltd Details
7.14.2 Sun Pharmaceutical Industries Ltd Major Business
7.14.3 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product and Services
7.14.4 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.14.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
7.14.6 Sun Pharmaceutical Industries Ltd Competitive Strengths & Weaknesses
8 RAW MATERIAL AND INDUSTRY CHAIN
8.1 Raw Material of Tumour Neoantigens and Key Manufacturers
8.2 Tumour Neoantigens Manufacturing Costs
8.3 Tumour Neoantigens Production Process
8.4 Tumour Neoantigens Industrial Chain
9 DISTRIBUTION CHANNEL ANALYSIS
9.1 Distribution Channel Breakdown for Tumour Neoantigens Shipments (%): 2017-2028
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 Tumour Neoantigens Typical Distributors
9.3 Tumour Neoantigens Typical Customers
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
LIST OF TABLES
Table 1. World Tumour Neoantigens Production Value by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Tumour Neoantigens Production Value by Region (2017-2022) & (USD Million)
Table 3. World Tumour Neoantigens Production Value by Region (2023-2028) & (USD Million)
Table 4. World Tumour Neoantigens Production Value Market Share by Region (2017-2022)
Table 5. World Tumour Neoantigens Production Value Market Share by Region (2023-2028)
Table 6. World Tumour Neoantigens Production by Region (2017-2022) & (K Units)
Table 7. World Tumour Neoantigens Production by Region (2023-2028) & (K Units)
Table 8. World Tumour Neoantigens Production Market Share by Region (2017-2022)
Table 9. World Tumour Neoantigens Production Market Share by Region (2023-2028)
Table 10. World Tumour Neoantigens Average Price by Region (2017-2022) & (US$/Unit)
Table 11. World Tumour Neoantigens Average Price by Region (2023-2028) & (US$/Unit)
Table 12. Tumour Neoantigens Major Market Trends
Table 13. World Tumour Neoantigens Consumption Growth Rate Forecast by Region (2017 & 2021 & 2028) & (K Units)
Table 14. World Tumour Neoantigens Consumption by Region (2017-2022) & (K Units)
Table 15. World Tumour Neoantigens Consumption Forecast by Region (2023-2028) & (K Units)
Table 16. World Tumour Neoantigens Production Value by Manufacturer (2017-2022) & (USD Million)
Table 17. Production Value Market Share of Key Tumour Neoantigens Producers in 2021
Table 18. World Tumour Neoantigens Production by Manufacturer (2017-2022) & (K Units)
Table 19. Production Market Share of Key Tumour Neoantigens Producers in 2021
Table 20. World Tumour Neoantigens Average Price by Manufacturer (2017-2022) & (US$/Unit)
Table 21. Global Tumour Neoantigens Company Evaluation Quadrant
Table 22. World Tumour Neoantigens Industry Rank of Major Manufacturers, Based on Production Value in 2021
Table 23. Head Office and Tumour Neoantigens Production Site of Key Manufacturer
Table 24. Tumour Neoantigens Market: Company Product Type Footprint
Table 25. Tumour Neoantigens Market: Company Product Application Footprint
Table 26. Tumour Neoantigens Competitive Factors
Table 27. Tumour Neoantigens New Entrant and Capacity Expansion Plans
Table 28. Tumour Neoantigens Mergers & Acquisitions Activity
Table 29. United States VS China Tumour Neoantigens Production Value Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 30. United States VS China Tumour Neoantigens Production Comparison, (2017 & 2021 & 2028) & (K Units)
Table 31. United States VS China Tumour Neoantigens Consumption Comparison, (2017 & 2021 & 2028) & (K Units)
Table 32. Major Manufacturer of Tumour Neoantigens in United States, Company Headquarters and Production Place (States, Country)
Table 33. United States Tumour Neoantigens Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 34. United States Tumour Neoantigens Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 35. United States Tumour Neoantigens Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 36. United States Tumour Neoantigens Production Market Share by Domestic Manufacturer, (2017-2022)
Table 37. Major Manufacturer of Tumour Neoantigens in China, Company Headquarters and Production Place (Province, Country)
Table 38. China Tumour Neoantigens Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 39. China Tumour Neoantigens Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 40. China Tumour Neoantigens Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 41. China Tumour Neoantigens Production Market Share by Domestic Manufacturer, (2017-2022)
Table 42. Major Manufacturer of Tumour Neoantigens in Rest of World, Company Headquarters and Production Place (State, Country)
Table 43. Rest of World Tumour Neoantigens Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 44. Rest of World Tumour Neoantigens Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 45. Rest of World Tumour Neoantigens Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 46. Rest of World Tumour Neoantigens Production Market Share by Domestic Manufacturer, (2017-2022)
Table 47. World Tumour Neoantigens Production Value by Type, (USD Million), 2017 & 2021 & 2028
Table 48. World Tumour Neoantigens Production by Type (2017-2022) & (K Units)
Table 49. World Tumour Neoantigens Production by Type (2023-2028) & (K Units)
Table 50. World Tumour Neoantigens Production Value by Type (2017-2022) & (USD Million)
Table 51. World Tumour Neoantigens Production Value by Type (2023-2028) & (USD Million)
Table 52. World Tumour Neoantigens Average Price by Type (2017-2022) & (US$/Unit)
Table 53. World Tumour Neoantigens Average Price by Type (2023-2028) & (US$/Unit)
Table 54. World Tumour Neoantigens Production Value by Application, (USD Million), 2017 & 2021 & 2028
Table 55. World Tumour Neoantigens Production by Application (2017-2022) & (K Units)
Table 56. World Tumour Neoantigens Production by Application (2023-2028) & (K Units)
Table 57. World Tumour Neoantigens Production Value by Application (2017-2022) & (USD Million)
Table 58. World Tumour Neoantigens Production Value by Application (2023-2028) & (USD Million)
Table 59. World Tumour Neoantigens Average Price by Application (2017-2022) & (US$/Unit)
Table 60. World Tumour Neoantigens Average Price by Application (2023-2028) & (US$/Unit)
Table 61. Achilles Therapeutics plc Basic Information, Manufacturing Base and Competitors
Table 62. Achilles Therapeutics plc Major Business
Table 63. Achilles Therapeutics plc Tumour Neoantigens Product and Services
Table 64. Achilles Therapeutics plc Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 65. Achilles Therapeutics plc Recent Developments/Updates
Table 66. Achilles Therapeutics plc Competitive Strengths & Weaknesses
Table 67. Advaxis Immunotherapies Basic Information, Manufacturing Base and Competitors
Table 68. Advaxis Immunotherapies Major Business
Table 69. Advaxis Immunotherapies Tumour Neoantigens Product and Services
Table 70. Advaxis Immunotherapies Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 71. Advaxis Immunotherapies Recent Developments/Updates
Table 72. Advaxis Immunotherapies Competitive Strengths & Weaknesses
Table 73. Genocea Basic Information, Manufacturing Base and Competitors
Table 74. Genocea Major Business
Table 75. Genocea Tumour Neoantigens Product and Services
Table 76. Genocea Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 77. Genocea Recent Developments/Updates
Table 78. Genocea Competitive Strengths & Weaknesses
Table 79. Gradalis, Inc Basic Information, Manufacturing Base and Competitors
Table 80. Gradalis, Inc Major Business
Table 81. Gradalis, Inc Tumour Neoantigens Product and Services
Table 82. Gradalis, Inc Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 83. Gradalis, Inc Recent Developments/Updates
Table 84. Gradalis, Inc Competitive Strengths & Weaknesses
Table 85. Gritstone bio Basic Information, Manufacturing Base and Competitors
Table 86. Gritstone bio Major Business
Table 87. Gritstone bio Tumour Neoantigens Product and Services
Table 88. Gritstone bio Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 89. Gritstone bio Recent Developments/Updates
Table 90. Gritstone bio Competitive Strengths & Weaknesses
Table 91. Iovance Biotherapetics Inc Basic Information, Manufacturing Base and Competitors
Table 92. Iovance Biotherapetics Inc Major Business
Table 93. Iovance Biotherapetics Inc Tumour Neoantigens Product and Services
Table 94. Iovance Biotherapetics Inc Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 95. Iovance Biotherapetics Inc Recent Developments/Updates
Table 96. Iovance Biotherapetics Inc Competitive Strengths & Weaknesses
Table 97. Medigene AG Basic Information, Manufacturing Base and Competitors
Table 98. Medigene AG Major Business
Table 99. Medigene AG Tumour Neoantigens Product and Services
Table 100. Medigene AG Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 101. Medigene AG Recent Developments/Updates
Table 102. Medigene AG Competitive Strengths & Weaknesses
Table 103. BioNTech SE Basic Information, Manufacturing Base and Competitors
Table 104. BioNTech SE Major Business
Table 105. BioNTech SE Tumour Neoantigens Product and Services
Table 106. BioNTech SE Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 107. BioNTech SE Recent Developments/Updates
Table 108. BioNTech SE Competitive Strengths & Weaknesses
Table 109. Lilly Basic Information, Manufacturing Base and Competitors
Table 110. Lilly Major Business
Table 111. Lilly Tumour Neoantigens Product and Services
Table 112. Lilly Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 113. Lilly Recent Developments/Updates
Table 114. Lilly Competitive Strengths & Weaknesses
Table 115. Scicomvisuals Basic Information, Manufacturing Base and Competitors
Table 116. Scicomvisuals Major Business
Table 117. Scicomvisuals Tumour Neoantigens Product and Services
Table 118. Scicomvisuals Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 119. Scicomvisuals Recent Developments/Updates
Table 120. Scicomvisuals Competitive Strengths & Weaknesses
Table 121. Moderna, Inc Basic Information, Manufacturing Base and Competitors
Table 122. Moderna, Inc Major Business
Table 123. Moderna, Inc Tumour Neoantigens Product and Services
Table 124. Moderna, Inc Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 125. Moderna, Inc Recent Developments/Updates
Table 126. Moderna, Inc Competitive Strengths & Weaknesses
Table 127. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 128. F. Hoffmann-La Roche Ltd Major Business
Table 129. F. Hoffmann-La Roche Ltd Tumour Neoantigens Product and Services
Table 130. F. Hoffmann-La Roche Ltd Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 131. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 132. F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses
Table 133. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 134. Merck KGaA Major Business
Table 135. Merck KGaA Tumour Neoantigens Product and Services
Table 136. Merck KGaA Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 137. Merck KGaA Recent Developments/Updates
Table 138. Sun Pharmaceutical Industries Ltd Basic Information, Manufacturing Base and Competitors
Table 139. Sun Pharmaceutical Industries Ltd Major Business
Table 140. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product and Services
Table 141. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 142. Tumour Neoantigens Raw Material
Table 143. Key Manufacturers of Tumour Neoantigens Raw Materials
Table 144. Tumour Neoantigens Typical Distributors
Table 145. Tumour Neoantigens Typical Customers
Table 1. World Tumour Neoantigens Production Value by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Tumour Neoantigens Production Value by Region (2017-2022) & (USD Million)
Table 3. World Tumour Neoantigens Production Value by Region (2023-2028) & (USD Million)
Table 4. World Tumour Neoantigens Production Value Market Share by Region (2017-2022)
Table 5. World Tumour Neoantigens Production Value Market Share by Region (2023-2028)
Table 6. World Tumour Neoantigens Production by Region (2017-2022) & (K Units)
Table 7. World Tumour Neoantigens Production by Region (2023-2028) & (K Units)
Table 8. World Tumour Neoantigens Production Market Share by Region (2017-2022)
Table 9. World Tumour Neoantigens Production Market Share by Region (2023-2028)
Table 10. World Tumour Neoantigens Average Price by Region (2017-2022) & (US$/Unit)
Table 11. World Tumour Neoantigens Average Price by Region (2023-2028) & (US$/Unit)
Table 12. Tumour Neoantigens Major Market Trends
Table 13. World Tumour Neoantigens Consumption Growth Rate Forecast by Region (2017 & 2021 & 2028) & (K Units)
Table 14. World Tumour Neoantigens Consumption by Region (2017-2022) & (K Units)
Table 15. World Tumour Neoantigens Consumption Forecast by Region (2023-2028) & (K Units)
Table 16. World Tumour Neoantigens Production Value by Manufacturer (2017-2022) & (USD Million)
Table 17. Production Value Market Share of Key Tumour Neoantigens Producers in 2021
Table 18. World Tumour Neoantigens Production by Manufacturer (2017-2022) & (K Units)
Table 19. Production Market Share of Key Tumour Neoantigens Producers in 2021
Table 20. World Tumour Neoantigens Average Price by Manufacturer (2017-2022) & (US$/Unit)
Table 21. Global Tumour Neoantigens Company Evaluation Quadrant
Table 22. World Tumour Neoantigens Industry Rank of Major Manufacturers, Based on Production Value in 2021
Table 23. Head Office and Tumour Neoantigens Production Site of Key Manufacturer
Table 24. Tumour Neoantigens Market: Company Product Type Footprint
Table 25. Tumour Neoantigens Market: Company Product Application Footprint
Table 26. Tumour Neoantigens Competitive Factors
Table 27. Tumour Neoantigens New Entrant and Capacity Expansion Plans
Table 28. Tumour Neoantigens Mergers & Acquisitions Activity
Table 29. United States VS China Tumour Neoantigens Production Value Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 30. United States VS China Tumour Neoantigens Production Comparison, (2017 & 2021 & 2028) & (K Units)
Table 31. United States VS China Tumour Neoantigens Consumption Comparison, (2017 & 2021 & 2028) & (K Units)
Table 32. Major Manufacturer of Tumour Neoantigens in United States, Company Headquarters and Production Place (States, Country)
Table 33. United States Tumour Neoantigens Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 34. United States Tumour Neoantigens Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 35. United States Tumour Neoantigens Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 36. United States Tumour Neoantigens Production Market Share by Domestic Manufacturer, (2017-2022)
Table 37. Major Manufacturer of Tumour Neoantigens in China, Company Headquarters and Production Place (Province, Country)
Table 38. China Tumour Neoantigens Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 39. China Tumour Neoantigens Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 40. China Tumour Neoantigens Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 41. China Tumour Neoantigens Production Market Share by Domestic Manufacturer, (2017-2022)
Table 42. Major Manufacturer of Tumour Neoantigens in Rest of World, Company Headquarters and Production Place (State, Country)
Table 43. Rest of World Tumour Neoantigens Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 44. Rest of World Tumour Neoantigens Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 45. Rest of World Tumour Neoantigens Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 46. Rest of World Tumour Neoantigens Production Market Share by Domestic Manufacturer, (2017-2022)
Table 47. World Tumour Neoantigens Production Value by Type, (USD Million), 2017 & 2021 & 2028
Table 48. World Tumour Neoantigens Production by Type (2017-2022) & (K Units)
Table 49. World Tumour Neoantigens Production by Type (2023-2028) & (K Units)
Table 50. World Tumour Neoantigens Production Value by Type (2017-2022) & (USD Million)
Table 51. World Tumour Neoantigens Production Value by Type (2023-2028) & (USD Million)
Table 52. World Tumour Neoantigens Average Price by Type (2017-2022) & (US$/Unit)
Table 53. World Tumour Neoantigens Average Price by Type (2023-2028) & (US$/Unit)
Table 54. World Tumour Neoantigens Production Value by Application, (USD Million), 2017 & 2021 & 2028
Table 55. World Tumour Neoantigens Production by Application (2017-2022) & (K Units)
Table 56. World Tumour Neoantigens Production by Application (2023-2028) & (K Units)
Table 57. World Tumour Neoantigens Production Value by Application (2017-2022) & (USD Million)
Table 58. World Tumour Neoantigens Production Value by Application (2023-2028) & (USD Million)
Table 59. World Tumour Neoantigens Average Price by Application (2017-2022) & (US$/Unit)
Table 60. World Tumour Neoantigens Average Price by Application (2023-2028) & (US$/Unit)
Table 61. Achilles Therapeutics plc Basic Information, Manufacturing Base and Competitors
Table 62. Achilles Therapeutics plc Major Business
Table 63. Achilles Therapeutics plc Tumour Neoantigens Product and Services
Table 64. Achilles Therapeutics plc Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 65. Achilles Therapeutics plc Recent Developments/Updates
Table 66. Achilles Therapeutics plc Competitive Strengths & Weaknesses
Table 67. Advaxis Immunotherapies Basic Information, Manufacturing Base and Competitors
Table 68. Advaxis Immunotherapies Major Business
Table 69. Advaxis Immunotherapies Tumour Neoantigens Product and Services
Table 70. Advaxis Immunotherapies Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 71. Advaxis Immunotherapies Recent Developments/Updates
Table 72. Advaxis Immunotherapies Competitive Strengths & Weaknesses
Table 73. Genocea Basic Information, Manufacturing Base and Competitors
Table 74. Genocea Major Business
Table 75. Genocea Tumour Neoantigens Product and Services
Table 76. Genocea Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 77. Genocea Recent Developments/Updates
Table 78. Genocea Competitive Strengths & Weaknesses
Table 79. Gradalis, Inc Basic Information, Manufacturing Base and Competitors
Table 80. Gradalis, Inc Major Business
Table 81. Gradalis, Inc Tumour Neoantigens Product and Services
Table 82. Gradalis, Inc Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 83. Gradalis, Inc Recent Developments/Updates
Table 84. Gradalis, Inc Competitive Strengths & Weaknesses
Table 85. Gritstone bio Basic Information, Manufacturing Base and Competitors
Table 86. Gritstone bio Major Business
Table 87. Gritstone bio Tumour Neoantigens Product and Services
Table 88. Gritstone bio Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 89. Gritstone bio Recent Developments/Updates
Table 90. Gritstone bio Competitive Strengths & Weaknesses
Table 91. Iovance Biotherapetics Inc Basic Information, Manufacturing Base and Competitors
Table 92. Iovance Biotherapetics Inc Major Business
Table 93. Iovance Biotherapetics Inc Tumour Neoantigens Product and Services
Table 94. Iovance Biotherapetics Inc Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 95. Iovance Biotherapetics Inc Recent Developments/Updates
Table 96. Iovance Biotherapetics Inc Competitive Strengths & Weaknesses
Table 97. Medigene AG Basic Information, Manufacturing Base and Competitors
Table 98. Medigene AG Major Business
Table 99. Medigene AG Tumour Neoantigens Product and Services
Table 100. Medigene AG Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 101. Medigene AG Recent Developments/Updates
Table 102. Medigene AG Competitive Strengths & Weaknesses
Table 103. BioNTech SE Basic Information, Manufacturing Base and Competitors
Table 104. BioNTech SE Major Business
Table 105. BioNTech SE Tumour Neoantigens Product and Services
Table 106. BioNTech SE Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 107. BioNTech SE Recent Developments/Updates
Table 108. BioNTech SE Competitive Strengths & Weaknesses
Table 109. Lilly Basic Information, Manufacturing Base and Competitors
Table 110. Lilly Major Business
Table 111. Lilly Tumour Neoantigens Product and Services
Table 112. Lilly Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 113. Lilly Recent Developments/Updates
Table 114. Lilly Competitive Strengths & Weaknesses
Table 115. Scicomvisuals Basic Information, Manufacturing Base and Competitors
Table 116. Scicomvisuals Major Business
Table 117. Scicomvisuals Tumour Neoantigens Product and Services
Table 118. Scicomvisuals Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 119. Scicomvisuals Recent Developments/Updates
Table 120. Scicomvisuals Competitive Strengths & Weaknesses
Table 121. Moderna, Inc Basic Information, Manufacturing Base and Competitors
Table 122. Moderna, Inc Major Business
Table 123. Moderna, Inc Tumour Neoantigens Product and Services
Table 124. Moderna, Inc Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 125. Moderna, Inc Recent Developments/Updates
Table 126. Moderna, Inc Competitive Strengths & Weaknesses
Table 127. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 128. F. Hoffmann-La Roche Ltd Major Business
Table 129. F. Hoffmann-La Roche Ltd Tumour Neoantigens Product and Services
Table 130. F. Hoffmann-La Roche Ltd Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 131. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 132. F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses
Table 133. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 134. Merck KGaA Major Business
Table 135. Merck KGaA Tumour Neoantigens Product and Services
Table 136. Merck KGaA Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 137. Merck KGaA Recent Developments/Updates
Table 138. Sun Pharmaceutical Industries Ltd Basic Information, Manufacturing Base and Competitors
Table 139. Sun Pharmaceutical Industries Ltd Major Business
Table 140. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product and Services
Table 141. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 142. Tumour Neoantigens Raw Material
Table 143. Key Manufacturers of Tumour Neoantigens Raw Materials
Table 144. Tumour Neoantigens Typical Distributors
Table 145. Tumour Neoantigens Typical Customers
LIST OF FIGURES
Figure 1. Tumour Neoantigens Picture
Figure 2. World Tumour Neoantigens Production Value: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Tumour Neoantigens Production Value and Forecast (2017-2028) & (USD Million)
Figure 4. World Tumour Neoantigens Production (2017-2028) & (K Units)
Figure 5. World Tumour Neoantigens Average Price (2017-2028) & (US$/Unit)
Figure 6. World Tumour Neoantigens Production Value Market Share by Region (2017-2028)
Figure 7. World Tumour Neoantigens Production Market Share by Region (2017-2028)
Figure 8. North America Tumour Neoantigens Production (2017-2028) & (K Units)
Figure 9. Europe Tumour Neoantigens Production (2017-2028) & (K Units)
Figure 10. China Tumour Neoantigens Production (2017-2028) & (K Units)
Figure 11. Japan Tumour Neoantigens Production (2017-2028) & (K Units)
Figure 12. Tumour Neoantigens Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Tumour Neoantigens Demand (2017-2028) & (K Units)
Figure 15. World Tumour Neoantigens Consumption Market Share by Region (2017-2028)
Figure 16. United States Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 17. China Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 18. Europe Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 19. Japan Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 20. South Korea Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 21. ASEAN Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 22. India Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 23. Producer Shipments of Tumour Neoantigens by Manufacturer Revenue ($MM) and Market Share (%): 2021
Figure 24. Global Four-firm Concentration Ratios (CR4) for Tumour Neoantigens Markets in 2021
Figure 25. Global Four-firm Concentration Ratios (CR8) for Tumour Neoantigens Markets in 2021
Figure 26. United States VS China: Tumour Neoantigens Production Value Market Share Comparison (2017 & 2021 & 2028)
Figure 27. United States VS China: Tumour Neoantigens Production Market Share Comparison (2017 & 2021 & 2028)
Figure 28. United States VS China: Tumour Neoantigens Consumption Market Share Comparison (2017 & 2021 & 2028)
Figure 29. Key Producers and Market Share of Tumour Neoantigens in United States
Figure 30. Key Producers and Market Share of Tumour Neoantigens in China
Figure 31. Key Producers and Market Share of Tumour Neoantigens in Rest of World
Figure 32. World Tumour Neoantigens Production Value by Type, (USD Million), 2017 & 2021 & 2028
Figure 33. World Tumour Neoantigens Production Value Market Share by Type in 2021
Figure 34. Common Neoantigens
Figure 35. Individualized Neoantigens
Figure 36. World Tumour Neoantigens Production Market Share by Type (2017-2028)
Figure 37. World Tumour Neoantigens Production Value Market Share by Type (2017-2028)
Figure 38. World Tumour Neoantigens Average Price by Type (2017-2028) & (US$/Unit)
Figure 39. World Tumour Neoantigens Production Value by Application, (USD Million), 2017 & 2021 & 2028
Figure 40. World Tumour Neoantigens Production Value Market Share by Application in 2021
Figure 41. T Cell Adoptive Therapy
Figure 42. DC Therapy
Figure 43. Therapeutic Vaccines
Figure 44. Other
Figure 45. World Tumour Neoantigens Production Market Share by Application (2017-2028)
Figure 46. World Tumour Neoantigens Production Value Market Share by Application (2017-2028)
Figure 47. World Tumour Neoantigens Average Price by Application (2017-2028) & (US$/Unit)
Figure 48. Manufacturing Cost Structure Analysis of Tumour Neoantigens in 2021
Figure 49. Manufacturing Process Analysis of Tumour Neoantigens
Figure 50. Tumour Neoantigens Industrial Chain
Figure 51. Distribution Channel Breakdown for Tumour Neoantigens Shipments (%): 2017-2028
Figure 52. Direct Channel Pros & Cons
Figure 53. Indirect Channel Pros & Cons
Figure 54. Methodology
Figure 55. Research Process and Data Source
Figure 1. Tumour Neoantigens Picture
Figure 2. World Tumour Neoantigens Production Value: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Tumour Neoantigens Production Value and Forecast (2017-2028) & (USD Million)
Figure 4. World Tumour Neoantigens Production (2017-2028) & (K Units)
Figure 5. World Tumour Neoantigens Average Price (2017-2028) & (US$/Unit)
Figure 6. World Tumour Neoantigens Production Value Market Share by Region (2017-2028)
Figure 7. World Tumour Neoantigens Production Market Share by Region (2017-2028)
Figure 8. North America Tumour Neoantigens Production (2017-2028) & (K Units)
Figure 9. Europe Tumour Neoantigens Production (2017-2028) & (K Units)
Figure 10. China Tumour Neoantigens Production (2017-2028) & (K Units)
Figure 11. Japan Tumour Neoantigens Production (2017-2028) & (K Units)
Figure 12. Tumour Neoantigens Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Tumour Neoantigens Demand (2017-2028) & (K Units)
Figure 15. World Tumour Neoantigens Consumption Market Share by Region (2017-2028)
Figure 16. United States Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 17. China Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 18. Europe Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 19. Japan Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 20. South Korea Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 21. ASEAN Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 22. India Tumour Neoantigens Consumption (2017-2028) & (K Units)
Figure 23. Producer Shipments of Tumour Neoantigens by Manufacturer Revenue ($MM) and Market Share (%): 2021
Figure 24. Global Four-firm Concentration Ratios (CR4) for Tumour Neoantigens Markets in 2021
Figure 25. Global Four-firm Concentration Ratios (CR8) for Tumour Neoantigens Markets in 2021
Figure 26. United States VS China: Tumour Neoantigens Production Value Market Share Comparison (2017 & 2021 & 2028)
Figure 27. United States VS China: Tumour Neoantigens Production Market Share Comparison (2017 & 2021 & 2028)
Figure 28. United States VS China: Tumour Neoantigens Consumption Market Share Comparison (2017 & 2021 & 2028)
Figure 29. Key Producers and Market Share of Tumour Neoantigens in United States
Figure 30. Key Producers and Market Share of Tumour Neoantigens in China
Figure 31. Key Producers and Market Share of Tumour Neoantigens in Rest of World
Figure 32. World Tumour Neoantigens Production Value by Type, (USD Million), 2017 & 2021 & 2028
Figure 33. World Tumour Neoantigens Production Value Market Share by Type in 2021
Figure 34. Common Neoantigens
Figure 35. Individualized Neoantigens
Figure 36. World Tumour Neoantigens Production Market Share by Type (2017-2028)
Figure 37. World Tumour Neoantigens Production Value Market Share by Type (2017-2028)
Figure 38. World Tumour Neoantigens Average Price by Type (2017-2028) & (US$/Unit)
Figure 39. World Tumour Neoantigens Production Value by Application, (USD Million), 2017 & 2021 & 2028
Figure 40. World Tumour Neoantigens Production Value Market Share by Application in 2021
Figure 41. T Cell Adoptive Therapy
Figure 42. DC Therapy
Figure 43. Therapeutic Vaccines
Figure 44. Other
Figure 45. World Tumour Neoantigens Production Market Share by Application (2017-2028)
Figure 46. World Tumour Neoantigens Production Value Market Share by Application (2017-2028)
Figure 47. World Tumour Neoantigens Average Price by Application (2017-2028) & (US$/Unit)
Figure 48. Manufacturing Cost Structure Analysis of Tumour Neoantigens in 2021
Figure 49. Manufacturing Process Analysis of Tumour Neoantigens
Figure 50. Tumour Neoantigens Industrial Chain
Figure 51. Distribution Channel Breakdown for Tumour Neoantigens Shipments (%): 2017-2028
Figure 52. Direct Channel Pros & Cons
Figure 53. Indirect Channel Pros & Cons
Figure 54. Methodology
Figure 55. Research Process and Data Source
